<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00941486</url>
  </required_header>
  <id_info>
    <org_study_id>FST100-AVC-02</org_study_id>
    <nct_id>NCT00941486</nct_id>
  </id_info>
  <brief_title>FST-100 Ophthalmic Suspension in Acute Adenoviral Conjunctivitis</brief_title>
  <official_title>A Randomized, Masked, Vehicle-controlled Clinical Trial to Assess the Safety and Efficacy of PVP-I (0.4%)/Dexamethasone (0.1%) Ophthalmic Suspension (Foresight Biotherapeutics, Inc) in the Treatment of Acute Adenoviral Conjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy of FST-100 (PVP-I 0.4% and&#xD;
      dexamethasone 0.1%) Ophthalmic Suspension in the treatment of suspected acute adenoviral&#xD;
      conjunctivitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">June 30, 2009</start_date>
  <completion_date type="Actual">June 30, 2010</completion_date>
  <primary_completion_date type="Actual">June 30, 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical cure is defined as a reduction of conjunctival injection and discharge scaled scored each to 0/3.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in viral titer by qPCR. Eradication of infectious virus determined by CC-IFA.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Acute Adenoviral Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>FST-100 Ophthalmic Suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FST-100 (PVP-I 0.4% and dexamethasone 0.1%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FST-100 Ophthalmic Suspension</intervention_name>
    <description>FST-100 (PVP-I 0.4% and dexamethasone 0.1%). A regimen of 2 drops 4 times a day while awake for 5 days.</description>
    <arm_group_label>FST-100 Ophthalmic Suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A regimen of 2 drops 4 times a day while awake for 5 days.</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Conjunctivitis within seven (7) days of initial ocular symptoms of redness and/or&#xD;
             discharge.&#xD;
&#xD;
          -  Clinical suspicion of adenoviral etiology.&#xD;
&#xD;
          -  At least three (3) years of age.&#xD;
&#xD;
          -  Subjects or their guardians capable of understanding the purpose and risks of the&#xD;
             study, and able to give informed consent.&#xD;
&#xD;
          -  Conjunctivitis diagnosis defined as presence of the two cardinal signs of acute&#xD;
             conjunctivitis:&#xD;
&#xD;
               1. conjunctival injection/inflammation, and&#xD;
&#xD;
               2. conjunctival discharge/exudates.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Conjunctivitis longer than 7 days after initial ocular symptoms.&#xD;
&#xD;
          -  Corneal ulcer, endophthalmitis, or any other confounding infection of the eye.&#xD;
&#xD;
          -  Patients taking ocular anti-inflammatory medications on a chronic basis.&#xD;
&#xD;
          -  Active herpes ocular infection.&#xD;
&#xD;
          -  Known or suspected pregnancy.&#xD;
&#xD;
          -  Known allergy to PVP-I.&#xD;
&#xD;
          -  Known allergy to dexamethasone.&#xD;
&#xD;
          -  Patients with a history of elevation in intraocular pressure as a result of steroid&#xD;
             use (&quot;steroid responders&quot;).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wolstan and Goldberg Eye Associates</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Eye Associates</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Center</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <zip>06518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Excellence in Eye</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ocean Ophthalmology</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33179</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Midwest Center for Sight</name>
      <address>
        <city>Des Plaines</city>
        <state>Illinois</state>
        <zip>60016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <zip>60169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silverstein Eye Centers</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Johns Clinic</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants PC The New York Eye and Ear Infirmary</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wantagh</city>
        <state>New York</state>
        <zip>11793</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus Ophthalmology Associates</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 15, 2009</study_first_submitted>
  <study_first_submitted_qc>July 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2009</study_first_posted>
  <disposition_first_submitted>September 5, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>September 5, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 6, 2012</disposition_first_posted>
  <last_update_submitted>August 22, 2021</last_update_submitted>
  <last_update_submitted_qc>August 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis, Inclusion</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

